Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far

Simple item page
dc.contributor.authorJadhav, Hemant R.
dc.date.accessioned2023-12-01T06:25:07Z
dc.date.available2023-12-01T06:25:07Z
dc.date.issued2015
dc.description.abstractRheumatoid Arthritis (RA) is an autoimmune disease characterized by persistent inflammation and joint damage. The main aim of RA treatment is to control the disease progress. Despite the success of biologicals like Adalimumab, Atlizumab, infliximab, etc. in treatment of RA, the high cost and associated immunological adverse effects have triggered discovery of small molecules targeting RA. This review describes the last 15 years of small molecular drug discovery in RA, focused mainly on preclinical and clinical studiesen_US
dc.identifier.urihttps://www.ingentaconnect.com/content/ben/mrmc/2015/00000015/00000002/art00005
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13295
dc.language.isoenen_US
dc.publisherBentham Scienceen_US
dc.subjectPharmacyen_US
dc.subjectJanus kinaseen_US
dc.subjectTNFα-converting enzymeen_US
dc.subjectTyrosine kinase inhibitors (TKIs)en_US
dc.subjectPeptidyl arginine deiminaseen_US
dc.subjectPhosphoinositide 3-kinaseen_US
dc.subjectRheumatoid arthritisen_US
dc.titleSmall Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Faren_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Department of Pharmacy